...
search icon
ctmx-img

CytomX Therapeutics Inc, Common Stock

CTMX

NSQ

$0.8639

+$0.02

(2.38%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$67.61M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
5.2506
Volume info-icon
This is the total number of shares traded during the most recent trading day.
585.60K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.06
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.79 L
$5.85 H
$0.8639

About CytomX Therapeutics Inc, Common Stock

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCTMXSectorS&P500
1-Week Return1.61%0.63%-1.11%
1-Month Return-24.22%6.06%0.39%
3-Month Return-14.47%0.46%4.94%
6-Month Return-31.44%0.42%15.68%
1-Year Return-40.42%3.52%21.45%
3-Year Return-79.72%11.44%33.25%
5-Year Return-89.19%44.83%81.76%
10-Year Return-93.3%112.91%193.72%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue57.49M100.36M69.57M53.16M101.21M[{"date":"2019-12-31","value":56.8,"profit":true},{"date":"2020-12-31","value":99.16,"profit":true},{"date":"2021-12-31","value":68.74,"profit":true},{"date":"2022-12-31","value":52.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue--5.84M5.86M2.17M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":99.71,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":37.14,"profit":true}]
Gross Profit57.49M100.36M69.57M53.16M101.21M[{"date":"2019-12-31","value":56.8,"profit":true},{"date":"2020-12-31","value":99.16,"profit":true},{"date":"2021-12-31","value":68.74,"profit":true},{"date":"2022-12-31","value":52.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses168.38M148.97M153.35M154.50M107.70M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":88.47,"profit":true},{"date":"2021-12-31","value":91.07,"profit":true},{"date":"2022-12-31","value":91.75,"profit":true},{"date":"2023-12-31","value":63.96,"profit":true}]
Operating Income(110.89M)(48.60M)(83.78M)(101.33M)(6.48M)[{"date":"2019-12-31","value":-11089500000,"profit":false},{"date":"2020-12-31","value":-4860500000,"profit":false},{"date":"2021-12-31","value":-8378100000,"profit":false},{"date":"2022-12-31","value":-10133500000,"profit":false},{"date":"2023-12-31","value":-648400000,"profit":false}]
Total Non-Operating Income/Expense16.59M3.65M427.00K3.70M17.87M[{"date":"2019-12-31","value":92.85,"profit":true},{"date":"2020-12-31","value":20.39,"profit":true},{"date":"2021-12-31","value":2.39,"profit":true},{"date":"2022-12-31","value":20.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(102.67M)(46.80M)(83.61M)(99.32M)3.32M[{"date":"2019-12-31","value":-3089.53,"profit":false},{"date":"2020-12-31","value":-1408.25,"profit":false},{"date":"2021-12-31","value":-2516.07,"profit":false},{"date":"2022-12-31","value":-2988.78,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes(427.00K)(13.91M)(2.96M)(2.02M)3.89M[{"date":"2019-12-31","value":-10.97,"profit":false},{"date":"2020-12-31","value":-357.43,"profit":false},{"date":"2021-12-31","value":-76.08,"profit":false},{"date":"2022-12-31","value":-51.85,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(102.24M)(32.88M)(80.65M)(97.30M)(569.00K)[{"date":"2019-12-31","value":-10223800000,"profit":false},{"date":"2020-12-31","value":-3288500000,"profit":false},{"date":"2021-12-31","value":-8064800000,"profit":false},{"date":"2022-12-31","value":-9729900000,"profit":false},{"date":"2023-12-31","value":-56900000,"profit":false}]
Income From Continuous Operations(102.24M)(32.88M)(83.61M)(115.87M)(10.18M)[{"date":"2019-12-31","value":-10223800000,"profit":false},{"date":"2020-12-31","value":-3288500000,"profit":false},{"date":"2021-12-31","value":-8360900000,"profit":false},{"date":"2022-12-31","value":-11587000000,"profit":false},{"date":"2023-12-31","value":-1018100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(102.24M)(32.88M)(80.65M)(97.30M)(569.00K)[{"date":"2019-12-31","value":-10223800000,"profit":false},{"date":"2020-12-31","value":-3288500000,"profit":false},{"date":"2021-12-31","value":-8064800000,"profit":false},{"date":"2022-12-31","value":-9729900000,"profit":false},{"date":"2023-12-31","value":-56900000,"profit":false}]
EPS (Diluted)(2.25)(0.72)(1.31)(1.52)(0.02)[{"date":"2019-12-31","value":-225,"profit":false},{"date":"2020-12-31","value":-72,"profit":false},{"date":"2021-12-31","value":-131,"profit":false},{"date":"2022-12-31","value":-152,"profit":false},{"date":"2023-12-31","value":-2,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CTMX
Cash Ratio 0.99
Current Ratio 1.04

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CTMX
ROA (LTM) 2.33%
ROE (LTM) -5475.03%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CTMX
Debt Ratio Lower is generally better. Negative is bad. 1.17
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.17

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CTMX
Trailing PE 5.40
Forward PE 14.20
P/S (TTM) 0.53
P/B 5.04
Price/FCF NM
EV/R 0.02
EV/Ebitda 3.86
PEG NM

FAQs

What is CytomX Therapeutics Inc share price today?

CytomX Therapeutics Inc (CTMX) share price today is $0.8639

Can Indians buy CytomX Therapeutics Inc shares?

Yes, Indians can buy shares of CytomX Therapeutics Inc (CTMX) on Vested. To buy CytomX Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CTMX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of CytomX Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of CytomX Therapeutics Inc (CTMX) via the Vested app. You can start investing in CytomX Therapeutics Inc (CTMX) with a minimum investment of $1.

How to invest in CytomX Therapeutics Inc shares from India?

You can invest in shares of CytomX Therapeutics Inc (CTMX) via Vested in three simple steps:

  • Click on Sign Up or Invest in CTMX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in CytomX Therapeutics Inc shares
What is CytomX Therapeutics Inc 52-week high and low stock price?

The 52-week high price of CytomX Therapeutics Inc (CTMX) is $5.85. The 52-week low price of CytomX Therapeutics Inc (CTMX) is $0.79.

What is CytomX Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of CytomX Therapeutics Inc (CTMX) is 5.2506

What is CytomX Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of CytomX Therapeutics Inc (CTMX) is 5.04

What is the Market Cap of CytomX Therapeutics Inc?

The market capitalization of CytomX Therapeutics Inc (CTMX) is $67.61M

What is CytomX Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of CytomX Therapeutics Inc is CTMX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top